// App-Quantinova.ai

e14577 : Determination of optimal dose and treatment schedule of the immunotherapeutic vaccine, DPX-Survivac, for combination immunotherapy treatment of ovarian, fallopian tube or peritoneal cancer (OC): A phase Ib study.

Researchers

Presenter

  • Jeannine A. Villella

Principal Investigators

  • Michelle K. Wilson

  • Neil Lorne Berinstein

  • Mohan Karkada

  • Tara Quinton

  • Marcus O. Butler

  • Stephanie Lheureux

  • Victoria Mandilaras

  • Neesha C. Dhani

  • Genevieve Weir

  • Lisa MacDonald

  • Rita Nigam

  • Marianne Stanford

  • Marc Mansour

  • Amit M. Oza

Medical Centers

  • Winthrop-University Hospital, Mineola, NY

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Immunovaccine, Inc., Halifax, NS, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • McGill University Health Centre, Montreal, QC, Canada

  • Immunovaccine, Inc., Halifax, NS, Canada

Locations

  • United States

  • Canada

Companies

  • IMV Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peritoneal cancer

Biomarkers

  • Peripheral blood mononuclear cell

  • Carbohydrate antigen 125

Drug/Treatment

  • EMD 640744

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01416038

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved